Bioneedles as alternative delivery system for hepatitis B vaccine

Journal of Controlled Release

Volumn 147, Issue 2, 2010, Pages 211-217

  Hirschberg, Hoang J H B ^a   van de Wijdeven, Gijsbert G P ^b   Kraan, Heleen ^a   Amorij, Jean Pierre ^a   Kersten, Gideon F A ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^b Bioneedle Technologies Group BV   (Netherlands)

Author keywords

Adjuvant; Bioneedle; Formulation; Freeze drying; Hepatitis B surface antigen; Stability

Indexed keywords

ADJUVANT; BIONEEDLE; FORMULATION; FREEZE DRYING; HEPATITIS B SURFACE ANTIGEN;

LIQUIDS; NEEDLES; VACCINES;

ANTIGENS;

HEPATITIS B SURFACE ANTIGEN ALUMINUM HYDROXIDE; HEPATITIS B SURFACE ANTIGEN LPXL1; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BIONEEDLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEEDLE; NONHUMAN; PRIORITY JOURNAL; THERMOSTABILITY;

ABSORBABLE IMPLANTS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOCOMPATIBLE MATERIALS; CIRCULAR DICHROISM; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREEZE DRYING; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED BALB C;

EID: 77957017058     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.06.028     Document Type: Article

References (32)

1. Jacobson R.M., Swan A., Adegbenro A., Ludington S.L., Wollan P.C., Poland G.A. Making vaccines more acceptable-methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine 2001, 19:2418-2427.
2. Nir Y., Paz A., Sabo E., Potasman I. Fear of injections in young adults: prevalence and associations. Am. J. Trop. Med. Hyg. 2003, 68:341-344.
3. Taddio A., Ilersich A.L., Ipp M., Kikuta A., Shah V. Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: systematic review of randomized controlled trials and quasi-randomized controlled trials. Clin. Ther. 2009, 31(Suppl 2):S48-S76.
4. Wright S., Yelland M., Heathcote K., Ng S.K., Wright G. Fear of needles-nature and prevalence in general practice. Aust. Fam. Physician 2009, 38:172-176.
5. Igietseme J.U., Eko F.O., He Q., Black C.M. Combination vaccines: design strategies and future trends. Expert Rev. Vaccin. 2006, 5:739-745.
6. Mallet E., Belohradsky B.H., Lagos R., et al. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 2004, 22:1343-1357.
7. Kersten G., Hirschberg H. Antigen delivery systems. Expert Rev. Vaccin. 2004, 3:453-462.
8. Aziz M.A., Midha S., Waheed S.M., Bhatnagar R. Oral vaccines: new needs, new possibilities. Bioessays 2007, 29:591-604.
9. Mann J.F., Acevedo R., Campo J.D., Perez O., Ferro V.A. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?. Expert Rev. Vaccin. 2009, 8:103-112.
10. Mestecky J., Russell M.W., Elson C.O. Perspectives on mucosal vaccines: is mucosal tolerance a barrier?. J. Immunol. 2007, 179:5633-5638.
11. Singh R., Singh S., Lillard J.W. Past, present, and future technologies for oral delivery of therapeutic proteins. J. Pharm. Sci. 2007, 97:2497-2523.
12. Arora Test A. Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 2008, 364:227-236.
13. El Maghraby G.M., Williams A.C., Barry B.W. Can drug-bearing liposomes penetrate intact skin?. J. Pharm. Pharmacol. 2006, 58:415-429.
14. Koutsonanos D.G., del Pilar M.M., Zarnitsyn V.G., et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS ONE 2009, 4:e4773.
15. Rai K., Gupta Y., Jain A., Jain S.K. Transfersomes: self-optimizing carriers for bioactives. PDA J. Pharm. Sci. Technol. 2008, 62:362-379.
16. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 2006, 22:68-89.
17. Mitragotri S. Current status and future prospects of needle-free liquid jet injectors. Nat. Rev. Drug Discov. 2006, 5:543-548.
18. Lofthouse S.A., Kajihara M., Nagahara S., et al. Injectable silicone implants as vaccine delivery vehicles. Vaccine 2002, 20(13-14):1725-1732.
19. Lloyd J.S. Technologies for Vaccine Delivery in the 21st Century World Health Organisation website. http://whqlibdoc.who.int/HQ/2000/WHO_V&B_00.35.pdf.
20. van de Wijdeven G.G. Development and assessment of mini projectiles as drug carriers. J. Control. Release 2002, 85:145-162.
21. Hirschberg H.J., van de Wijdeven G.G., Kelder A.B., van den Dobbelsteen G.P., Kersten G.F. Bioneedles as vaccine carriers. Vaccine 2008, 26:2389-2397.
22. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47:401-409.
23. Maa Y.F., Zhao L., Payne L.G., Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J. Pharm. Sci. 2003, 92:319-332.
24. Arigita C., Luijkx T., Jiskoot W., et al. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives. Vaccine 2005, 23:5091-5098.
25. de Vries J.J., Bungener L., Ter Veer V.W., et al. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. Vaccine 2009, 27:947-955.
26. Jain V., Sahu R., Misra-Bhattacharya S., Vyas S.P., Kohli D. Enhancement of T-helper type I immune responses against hepatitis B surface antigen by LPS derivatives adjuvanted liposomes delivery system. J. Drug Target. 2008, 16:706-715.
27. Galazka A., Milstien J., Zaffran M. Thermostability of Vaccines, 1998 Report. http://whqlibdoc.who.int/HQ/1998/WHO_GPV_98.07.pdf.
28. Creati M., Saleh A., Ruff TA T.A., et al. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. Vaccine 2007, 25:5985-5993.
29. Hipgrave D.B., Maynard J.E., Biggs B.A. Improving birth dose coverage of hepatitis B vaccine. Bull. World Health Organ. 2006, 84:65-71.
30. Hipgrave D.B., Tran T.N., Huong V.M., et al. Immunogenicity of a locally produced hepatitis B vaccine with the birth dose stored outside the cold chain in rural Vietnam. Am. J. Trop. Med. Hyg. 2006, 74:255-260.
31. Gomez-Gutierrez J., Rodriguez-Crespo I., Gonzalez-Ros J.M., et al. Thermal stability of hepatitis B surface antigen S proteins. Biochim. Biophys. Acta 1992, 1119:225-231.
32. Diminsky D., Moav N., Gorecki M., Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 1999, 18:3-17.